OFFERED FOR CONSIDERATION 2/9/2022 03:00:51 PM

1	SENATE BILL NO. 711
2	AMENDMENT IN THE NATURE OF A SUBSTITUTE
3	(Proposed by the Senate Committee on Education and Health
4	on February 10, 2022)
5	(Patron Prior to SubstituteSenator Chase)
6	A BILL to amend the Code of Virginia by adding sections numbered 54.1-2963.3, 54.1-3005.2, and 54.1-
7	3303.2, relating to treatment of COVID-19.
8	Be it enacted by the General Assembly of Virginia:
9	1. That the Code of Virginia is amended by adding sections numbered 54.1-2963.3, 54.1-3005.2, and
10	54.1-3303.2 as follows:
11	§ 54.1-2963.3. Treatment of COVID-19.
12	The Board shall not threaten, deny, revoke, suspend, or otherwise take investigatory,
13	administrative, or disciplinary action against a physician, physician assistant, or nurse practitioner on the
14	basis of any of the following:
15	1. Prescribing to a patient for prevention of or treatment therapy for COVID-19, for use in the
16	patient's home or in any health care facility, any or all of the following:
17	a. Hydroxychloroquine;
18	b. Chloroquine;
19	c. Azithromycin;
20	d. Ivermectin;
21	e. Methylprednisolone;
22	f. Prednisone;
23	g. Naltrexone;
24	h. Ascorbic acid;
25	i. Thiamine;
26	i Rudesonide:

27	k. Nitazoxanide;
28	1. Colchicine;
29	m. Fluvoxamine;
30	n. Cyproheptadine;
31	o. Spironolactone;
32	p. Dutasteride;
33	q. Flutamide;
34	r. Famotidine;
35	s. Heparin;
36	t. Atorvastatin;
37	u. N-Acetyl-L-Cysteine;
38	v. Vitamin D;
39	w. Zinc;
40	x. Aspirin; or
41	y. Melatonin.
42	2. Administering to a patient for prevention of or treatment therapy for COVID-19, for use in the
43	patient's home or in any health care facility, any of the medications or supplements listed in subdivision
44	<u>1.</u>
45	3. Providing medical exemptions to patients who are unable to wear a mask, undergo a test for
46	COVID-19, or receive a COVID-19 vaccine.
47	4. Treating patients who for religious, medical, or philosophical reasons are unable to wear a mask,
48	undergo a test for COVID-19, or receive a COVID-19 vaccine.
49	5. Documenting and reporting COVID-19 vaccine injury.
50	6. Discussing with or informing a patient, a family member, or the public about prevention of or
51	treatment therapy for COVID-19 or advocating for, in any setting, the use of any or all of the medications
52	or supplements listed in subdivision 1.
53	§ 54.1-3005.2. Treatment of COVID-19.

54	The Board shall not threaten, deny, revoke, suspend, or otherwise take investigatory,
55	administrative, or disciplinary action against a registered nurse or licensed practical nurse on the basis of
56	any of the following:
57	1. Administering to a patient a prescription for prevention of or treatment therapy for COVID-19,
58	for use in the patient's home or in any health care facility, any or all of the following:
59	a. Hydroxychloroquine;
60	b. Chloroquine;
61	c. Azithromycin;
62	d. Ivermectin;
63	e. Methylprednisolone;
64	<u>f. Prednisone;</u>
65	g. Naltrexone;
66	h. Ascorbic acid;
67	i. Thiamine;
68	j. Budesonide;
69	k. Nitazoxanide;
70	1. Colchicine;
71	m. Fluvoxamine;
72	n. Cyproheptadine;
73	o. Spironolactone;
74	p. Dutasteride;
75	q. Flutamide;
76	r. Famotidine;
77	s. Heparin;
78	t. Atorvastatin;
79	u. N-Acetyl-L-Cysteine;
80	v. Vitamin D;

81	w. Zinc;
82	x. Aspirin; or
83	y. Melatonin.
84	2. Documenting and reporting COVID-19 vaccine injury.
85	3. Discussing with or informing a patient, a family member, or the public about prevention of or
86	treatment therapy for COVID-19 or advocating for, in any setting, the use of any or all of the medications
87	or supplements listed in subdivision 1.
88	§ 54.1-3303.2. Treatment of COVID-19.
89	The Board shall not threaten, deny, revoke, suspend, or otherwise take investigatory,
90	administrative, or disciplinary action against a pharmacist on the basis of any of the following:
91	1. Filling a prescription for prevention of or treatment therapy for COVID-19, for use in the
92	patient's home or in any health care facility, any or all of the following:
93	a. Hydroxychloroquine;
94	b. Chloroquine;
95	c. Azithromycin;
96	d. Ivermectin;
97	e. Methylprednisolone;
98	<u>f. Prednisone;</u>
99	g. Naltrexone;
100	h. Ascorbic acid;
101	i. Thiamine;
102	j. Budesonide;
103	k. Nitazoxanide;
104	1. Colchicine;
105	m. Fluvoxamine;
106	n. Cyproheptadine;
107	o. Spironolactone;

DRAFT

OFFERED FOR CONSIDERATION

2/9/2022 03:00:51 PM

108	p. Dutasteride;
109	q. Flutamide;
110	r. Famotidine;
111	s. Heparin;
112	t. Atorvastatin;
113	u. N-Acetyl-L-Cysteine;
114	v. Vitamin D;
115	w. Zinc;
116	x. Aspirin; or
117	y. Melatonin.
118	2. Documenting and reporting COVID-19 vaccine injury.
119	3. Discussing with or informing a patient, a family member, or the public about prevention of or
120	treatment therapy for COVID-19 or advocating for, in any setting, the use of any or all of the medications
121	or supplements listed in subdivision 1.
122	#